Differences in Treatment Response in Bronchial Epithelial Cells from Idiopathic Pulmonary Fibrosis (IPF) Patients: A First Step towards Personalized Medicine?

Differences in Treatment Response in Bronchial Epithelial Cells from Idiopathic Pulmonary Fibrosis (IPF) Patients: A First Step towards Personalized Medicine?

Idiopathic pulmonary fibrosis (IPF) has a detrimental prognosis despite antifibrotic therapies to which individual responses vary. IPF pathology is associated with oxidative stress, inflammation and increased activation of SRC family kinases (SFK). This pilot study evaluates individual responses to...

Full description

Bibliographic Details
Main Authors: C. Veith, M. A. Schneider, L. Maas, A. van der Vliet, F. J. van Schooten, M. Kreuter, M. Meister, A. W. Boots, N. Kahn
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Antioxidants
Subjects:
IPF
primary bronchial epithelial cells
nintedanib
pirfenidone
saracatinib
personalized medicine
Online Access:https://www.mdpi.com/2076-3921/12/2/443

Internet

https://www.mdpi.com/2076-3921/12/2/443

Similar Items